← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cytosorbents, Inc.
Princeton, NJ
$4,237,176
Total funding
4
Grants
Funding over time
peak $996K · FY2013–23$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,237,176 · 4
By mechanism
R44$2,970,974 · 1
N44$774,516 · 1
R43$288,335 · 1
N43$203,351 · 1
Investigators at Cytosorbents, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
pRBC Contaminant Removal with Hemocompatible Porous Polymer Beads$995,984
R44 · FY2018 · HL
pRBC Contaminant Removal with Hemocompatible Porous Polymer Beads$991,940
R44 · FY2020 · HL
pRBC Contaminant Removal with Hemocompatible Porous Polymer Beads$983,050
R44 · FY2019 · HL
IGF::OT::IGF To develop HemoDefend, hemocompatible, highly porous polymer beads optimized to broadly remove freehemoglobin, potassium, reactive antibodies, and inflammatory or reactive substances from$774,516
N44 · FY2016 · HL
Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability$281,835
R43 · FY2022 · GM
DEVELOP A HEMOCOMPATIBLE, EASY-TO-USE, COST-EFFECTIVE BLOOD PURIFIC$203,351
N43 · FY2013 · HL
Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability$6,500
R43 · FY2023 · GM